Ingrid Zhang- CEO of Legend Biotech and a Leader in Global Biopharmaceuticals

Ingrid Zhang is the chief executive officer of Legend Biotech, a global biotechnology company focused on developing and commercializing cell therapies for cancer and other serious diseases. She took the role on September 15, 2026, bringing extensive experience in pharmaceutical commercialization, international business leadership, and the launch of innovative medicines.

Before joining Legend Biotech, Zhang served as chief commercial officer for Novartis International. During her 15-year career at Novartis, she also led the company's China business and held senior leadership positions in Poland. Earlier in her career, she worked at AstraZeneca, Pfizer, and McKinsey & Company.

Her appointment comes at an important stage for Legend Biotech. The company is working to expand the commercial reach of CARVYKTI, its approved CAR-T cell therapy for multiple myeloma, while advancing a broader pipeline of cell therapy treatments. Zhang's experience leading pharmaceutical businesses across international markets gives her a commercial and operational perspective as Legend pursues its next phase of growth. 

Who Is Ingrid Zhang?

Ingrid Zhang is a global biopharmaceutical executive whose career has focused on pharmaceutical strategy, commercial operations, market expansion, and bringing innovative medicines to patients.

She became CEO of Legend Biotech on September 15, 2026, following a board-led executive search. She succeeded Alan Bash, who had served as interim CEO since July 2026 and returned to his role as president of CARVYKTI.

Legend Biotech's board selected Zhang for her experience managing complex international pharmaceutical businesses and leading commercial organizations. Her background includes responsibility for major markets, product launch strategy, and the commercial development of innovative medicines.

Unlike executives whose careers are primarily rooted in laboratory research or drug discovery, Zhang has built much of her experience around the business side of healthcare: helping pharmaceutical companies bring treatments to market, expand patient access, and develop sustainable commercial operations. 

Education and Professional Background

Zhang holds a master's degree in chemical engineering from Pennsylvania State University and an MBA in finance and strategy from the Wharton School of the University of Pennsylvania.

Her academic background combines technical knowledge with business and financial training. This combination has been relevant throughout her career in an industry where scientific innovation must be supported by commercial strategy, market access, and complex international operations. 

She began her professional career at McKinsey & Company, where she focused on healthcare consulting. The experience gave her exposure to the strategic and operational challenges facing pharmaceutical and healthcare organizations.

She subsequently moved into the pharmaceutical industry, taking management positions at Pfizer and AstraZeneca before joining Novartis in 2011. 

Career at Novartis

Zhang spent approximately 15 years at Novartis, one of the world's largest pharmaceutical companies. Her career there included leadership positions in Europe, China, and international commercial operations.

Her progression through the organization reflects experience in both individual country markets and global pharmaceutical strategy.

Leading Novartis in Poland

From 2015 to 2017, Zhang served as Country Pharma Organization Head and Country President in Poland.

She was responsible for commercial operations and strategic initiatives in the market. The role gave her experience leading a national pharmaceutical business and managing the relationship between global product strategy and local healthcare systems.

Operating in a country market requires an understanding of local regulations, healthcare priorities, physicians, patients, and reimbursement structures. Zhang's experience in Poland added an important international dimension to her leadership background. 

President of Novartis Pharmaceuticals China

In 2017, Zhang became president of Novartis Pharmaceuticals China, a position she held through June 2022.

She led the pharmaceutical business during a period when China was an increasingly important market for multinational drug companies. Her responsibilities included commercial performance, business growth, and expanding access to innovative medicines.

Her work involved navigating a complex healthcare environment while developing the company's position in one of the world's largest pharmaceutical markets. 

President and Managing Director of Novartis China

Zhang subsequently became president and managing director of Novartis China, serving from 2023 to 2024.

In this role, she focused on long-term strategic planning, accelerating growth, improving access to innovative medicines, and strengthening the company's relationship with the wider Chinese healthcare community.

The position required leadership across a large national business and coordination between commercial priorities, corporate strategy, and the needs of patients and healthcare providers. 

Chief Commercial Officer, International

In June 2024, Zhang became chief commercial officer for Novartis International.

She led the Commercial Launch Strategy team, which developed and implemented strategies for new product launches. For established medicines, the team worked to expand patient impact by optimizing commercial strategies and improving execution.

This role placed Zhang closer to the international launch and growth strategies for Novartis medicines. It also gave her experience coordinating commercial priorities across different countries and healthcare markets.

She remained in the position until August 2026, shortly before joining Legend Biotech. 

Board Experience at Mettler-Toledo

Alongside her pharmaceutical leadership career, Zhang served on the board of directors of Mettler-Toledo International, a global manufacturer of precision instruments and related services.

Mettler-Toledo serves customers in laboratory, industrial, and food retail markets. Its products include laboratory weighing equipment, analytical instruments, and industrial measurement systems.

The board role gave Zhang experience outside the pharmaceutical sector, particularly in corporate governance and the oversight of an international technology and manufacturing business. 

Ingrid Zhang as CEO of Legend Biotech

Legend Biotech is a biotechnology company focused on cell therapies, particularly chimeric antigen receptor T-cell (CAR-T) treatments for cancer.

CAR-T therapy is a form of immunotherapy that uses a patient's own T cells, modified to recognize and attack cancer cells. It represents an important area of development in the treatment of certain blood cancers.

Legend's business combines research and development with the manufacturing, regulatory, and commercial capabilities required to bring cell therapies to patients.

The company's flagship product is CARVYKTI, developed and commercialized in collaboration with Johnson & Johnson. 

CARVYKTI: Legend's Flagship Therapy

CARVYKTI (ciltacabtagene autoleucel) is a CAR-T cell therapy for adults with relapsed or refractory multiple myeloma, a blood cancer affecting plasma cells.

The treatment is developed by Legend Biotech in collaboration with Johnson & Johnson's Janssen organization. The partnership combines Legend's cell therapy research and development capabilities with Johnson & Johnson's global pharmaceutical and commercial infrastructure.

CARVYKTI is central to Legend's current commercial business. Its growth depends on several factors, including physician adoption, manufacturing capacity, patient eligibility, treatment-center availability, and the ability to reach patients who may benefit from the therapy.

For Zhang, expanding the product's commercial reach while supporting its continued development is one of the most important responsibilities of her new position. 

Expanding Beyond a Single Commercial Product

Legend Biotech's longer-term strategy extends beyond CARVYKTI.

The company is working to build a broader cell therapy business by developing additional treatments and expanding its technology capabilities. This includes advancing its pipeline across different cell therapy approaches and exploring opportunities to apply its expertise to additional diseases.

Zhang's appointment reflects the importance of commercial leadership as Legend moves from establishing its first major product toward building a more diversified biotechnology business.

Her experience at Novartis is relevant to this challenge. She has led organizations responsible for product launches, international commercial strategy, and business growth across multiple pharmaceutical markets. 

Strategic Priorities Under Ingrid Zhang

Legend Biotech appointed Zhang at a time when the company must balance the growth of an established commercial therapy with the development of future products.

Her initial priorities can be understood through the company's stated strategy and the experience she brings to the role.

1. Expanding CARVYKTI's Global Reach

CARVYKTI is the foundation of Legend's commercial business. Increasing patient access and supporting the treatment's adoption across eligible markets will be central to the company's growth.

Zhang's international commercial experience could help Legend coordinate market development, commercial execution, and relationships with healthcare providers.

2. Advancing the Cell Therapy Pipeline

Legend's future depends on developing additional treatments that can build on its experience with CAR-T technology.

The company intends to expand its pipeline and develop new cell therapy modalities. Zhang has said that advancing the pipeline is among her priorities as CEO.

Her role will involve ensuring that commercial strategy and business planning support the company's research and development ambitions. 

3. Strengthening Commercial Operations

Launching and expanding advanced therapies requires more than conventional pharmaceutical sales and marketing.

Cell therapies involve specialized manufacturing, treatment-center infrastructure, physician education, patient identification, and coordination across healthcare systems.

Zhang's experience leading commercial launch strategies at Novartis is particularly relevant to these operational challenges.

4. Building a Sustainable Biopharmaceutical Business

Legend has more than 3,000 employees and is developing an organization that combines research, manufacturing, and commercialization.

As CEO, Zhang must help the company manage its resources, partnerships, and growth opportunities while maintaining its focus on scientific innovation and patient outcomes.

The challenge is to translate the success of CARVYKTI into a sustainable business with additional products and a broader commercial foundation. 

Leadership Style and Business Philosophy

Zhang's career suggests a leadership approach built around international collaboration, commercial execution, and strategic growth.

Her experience spans consulting, country-level pharmaceutical leadership, and global commercial strategy. These positions have required her to work across different healthcare systems and coordinate teams with varied responsibilities.

Several themes stand out:

• International business leadership: Her roles in Poland, China, and global Novartis operations gave her experience managing pharmaceutical businesses across different markets.

• Commercial execution: Her work on product launch strategies focused on turning pharmaceutical innovation into broader patient access and business results.

• Strategic planning: Her leadership positions in China involved long-term planning, market development, and growth initiatives.

• Cross-functional management: Her experience across commercial and international organizations required coordination between business strategy, product teams, and local operations.

• Patient access: Her work at Novartis included expanding access to innovative medicines and strengthening commercial strategies around established products.

These themes provide insight into the experience she brings to Legend Biotech. Her leadership at the company will ultimately be evaluated through its commercial performance, pipeline progress, and ability to make cell therapies available to more patients. 

Key Facts About Ingrid Zhang

Detail	Information
Full name	Ingrid Zhang
Current position	Chief Executive Officer of Legend Biotech
CEO since	September 15, 2026
Industry	Biotechnology and biopharmaceuticals
Previous company	Novartis
Most recent previous role	Chief Commercial Officer, International, Novartis
Previous leadership roles	President and Managing Director of Novartis China; President of Novartis Pharmaceuticals China; Country President in Poland
Earlier career	McKinsey & Company, Pfizer, AstraZeneca
Education	Master's in Chemical Engineering, Pennsylvania State University
Graduate business degree	MBA, Wharton School, University of Pennsylvania
Board experience	Mettler-Toledo International
Flagship product at Legend	CARVYKTI

 

Why Ingrid Zhang Matters in Biotechnology

Ingrid Zhang's appointment represents an important leadership transition for Legend Biotech as the company works to establish itself as a broader cell therapy business.

The biotechnology industry is full of companies developing promising treatments, but moving from scientific discovery to successful commercialization is a demanding process. It requires manufacturing capabilities, regulatory execution, commercial infrastructure, partnerships, and access to healthcare systems.

Zhang brings substantial experience in these areas from her years at Novartis. She has led pharmaceutical businesses in major international markets and worked on strategies for launching innovative medicines.

At Legend Biotech, her challenge is to apply that experience to a specialized and rapidly developing area of medicine. The company's ability to grow CARVYKTI, advance its pipeline, and develop a sustainable commercial platform will be central to evaluating her leadership.

Her appointment places an experienced international pharmaceutical executive at the head of a company working to expand the role of cell therapy in cancer treatment.

About Legend Biotech

Legend Biotech is a global biotechnology company focused on the discovery, development, manufacturing, and commercialization of cell therapies for cancer and other serious diseases.

Its flagship product, CARVYKTI, is a CAR-T cell therapy for relapsed or refractory multiple myeloma, developed and commercialized in collaboration with Johnson & Johnson.

The company is working to expand its cell therapy pipeline and build an integrated business that connects scientific research, manufacturing, and patient access.